Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
Executive Summary
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
You may also be interested in...
Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem
Bristol says it's too early to make predictions for future immunotherapy regimens based on new tumor mutation burden analysis of the failed Opdivo Checkmate 026 trial aired at the AACR meeting, but the company plans to fully explore this important biomarker.
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.